Last updated: March 2, 2026
What is NDC 83324-0121?
NDC 83324-0121 refers to Prevymis (letermovir), a viral DNA terminase complex inhibitor approved by the FDA in June 2017. It is used for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive ordinary recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
Market Size and Drivers
Current Market Size
- The global antiviral drugs market reached $33.4 billion in 2022 (source: Grand View Research).
- The segment for post-transplant viral infection prophylaxis accounts for approximately 12% of this market, with a focus on CMV-related treatments.
- NDC 83324-0121 (Prevymis) occupied an estimated $250 million in U.S. sales in 2022 (IQVIA).
Key Factors
- Increasing number of HSCT procedures drives demand.
- Rising prevalence of CMV infections among immunocompromised patients.
- Expanding indications and off-label use.
Competitive Landscape
Major competitors include:
- Ganciclovir (Genciclovir)
- Valganciclovir (Valcyte)
- Letermovir faces competition primarily from off-label and generic therapies; however, it maintains a niche due to favorable safety and dosing profile.
The market is characterized by:
- Limited direct competition due to unique mechanism.
- Growing adoption facilitated by recent clinical guidelines favoring letermovir for prophylaxis.
Pricing Structure and Trends
Wholesale Acquisition Cost (WAC)
- The WAC for a 4 mg tablet of Prevymis in 2023 stands at approximately $530 per tablet.
- The typical treatment course involves daily dosing over 100 days post-transplant, totaling roughly $53,000 per patient.
Price Trends
- The price has remained stable since FDA approval but has faced scrutiny from payers.
- Manufacturers consider differential pricing for government vs. private insurers.
- Discounting and rebates are prevalent, reducing acquisition costs by approximately 20-30%.
Market Access Dynamics
- Insurance coverage is widespread, with formularies favoring Prevymis for its safety profile.
- The high cost influences payer negotiations, potentially affecting net prices.
Future Price Projections
Short-term (Next 1-2 Years)
- Prices are expected to remain stable due to drug exclusivity.
- Market entry of generics is unlikely until 2032, due to patent protections.
- Price negotiations and rebates could marginally reduce net costs.
Medium-term (3-5 Years)
- Patent expiry in 2032 could lead to generic entry.
- Competition might reduce WAC prices by 30-50%, potentially bringing the cost per treatment course down to $26,500 to $36,500.
- Biosimilar or alternative technologies could emerge, adding downward pressure.
Long-term (Beyond 5 Years)
- Further generics or biosimilars could induce price erosion exceeding 50%.
- Potential introduction of improved formulations or combination therapies might impact pricing dynamics.
Regulatory and Patent Outlook
- Patent protections are expected to expire in 2032.
- No significant patent litigation or supplementary patents are reported that could extend exclusivity.
- The landscape may shift with parallel development of novel CMV prophylaxis agents.
Key Takeaways
- The current U.S. market value for Prevymis is approximately $250 million annually.
- The drug's price per course remains around $53,000 but is subject to rebates and discounts.
- Market growth hinges on increased HSCT procedures and CMV management needs.
- Entry of generics post-2032 is projected to significantly lower prices.
- Clinical adoption correlates strongly with evolving treatment guidelines and payer policies.
FAQs
1. What factors limit the immediate price reduction of Prevymis?
Patent exclusivity and manufacturer-controlled supply sustain pricing. Limited generic competition until 2032 maintains high WAC.
2. How might payer negotiations influence net prices?
Payers demand rebates and discounts, possibly reducing net costs by 20-30%, balancing high list prices.
3. What drives demand for letermovir?
Increasing HSCT procedures, CMV infection rates among immunocompromised patients, and favorable safety profiles.
4. When is generic entry expected?
Patent expiry is anticipated in 2032, after which generics could enter the market, reducing prices.
5. How does the competitive landscape affect future pricing?
Limited direct competitors now, but off-label use and emerging therapies could influence pricing strategies over time.
References
- Grand View Research. (2022). Antiviral Drugs Market Size, Share & Trends Analysis Report.
- IQVIA. (2022). U.S. Prescription Data on Prevymis.
- FDA. (2017). Approval of letermovir for CMV prophylaxis.
- PatentScope. (2022). Patent landscape for letermovir.
- European Medicine Agency. (2017). Summary of Product Characteristics for Prevymis.
